



**Major expansion of our  
Premium Program in  
the field of cancer prevention.**

Dear Premium Customers,

**In expanding our premium program, we have  
relied heavily on research findings from our  
Salvagene Cancer Prevention Center.**

Several hundred new genetic polymorphisms have been added to our panel, especially in the areas of skin cancer, prostate cancer, colon cancer, lung cancer and breast cancer.

This has led to reweighting within our Salvagene A.I. Program, for example in prostate cancer prevention. Long-term supply of boron and early PSA are now weighted almost three times more than before. In the field of breast cancer prevention, the weighting for 2/16 OH ratio has increased fivefold.

But apart from cancer prevention, the program now includes around 120 additional genetic polymorphisms and epigenetic markers. For example, genetic predisposition for possible telomere extension and its cofactors, as well as predisposition towards resilience and thus performance in stressful situations.

In addition, epigenetic and genetic markers are tested for predisposition to depression and for the efficacy of SSRIs.

We have also significantly expanded our biochemical panel in terms of the TNF-alpha inhibition test. The efficacy of anti-inflammatory substances varies widely between patients due to the strongly differing and individual expression of toll-like receptors (TLRs) on macrophages. We have extended this inflammation inhibition test from the previous eight anti-inflammatory substances to more than five hundred with immediate effect. Because the expression of toll-like receptors is constantly changing in humans, it makes sense to perform this test annually and to formulate the most effective anti-inflammatory supplements.

All of these new features are part of the Premium Program with immediate effect and will be updated free of charge for all existing Premium Customers. Details of the new program components will be announced as follows:

- October 2019: Prostate cancer prevention Salvagene A.I.
- November 2019: Breast cancer prevention Salvagene A.I.
- December 2019: Extension of the gene panel for skin cancer and colon cancer
- January 2020: Extension of the gene panel for schizophrenia and depression
- February 2020: Extension of the gene panel for burnout and depression
- March 2020: Extension of the gene panel for telomere lengthening strategy

**SALVAGENE HQ**  
Université Paris Sorbonne  
125 Rue Saint-Jacques, 75005 Paris

**SALVAGENE UK**  
55 Bryanston Street • London, W1H 7AA  
Tel: 0044 20 3287 0644

**SALVAGENE USA**  
100 Park Avenue • New York, NY10017  
Tel: +1 646 583 0999

[info@salvagene.com](mailto:info@salvagene.com) • [www.salvagene.com](http://www.salvagene.com)